K. S. Carmon

This study develops an antibody-drug conjugate targeting GPR56 and shows it is effective against colorectal cancer models.

This study shows that loss of LGR5 in colorectal cancer cells through plasticity or gene ablation activates MET-STAT3 signaling, leading to therapy resistance and suggesting new treatment strategies targeting plasticity.

This paper develops RSPO4 mutant-based peptibody drug conjugates that target LGR4/5/6, showing potent cytotoxic effects and tumor suppression in vitro and in vivo.

This study identifies enhancer subtypes in colorectal cancer through epigenomic analysis and proposes targeted therapeutic strategies based on these subtypes.

The paper shows that the RNF43-G659Vfs41 mutation is functional and not a driver mutation in tumorigenesis, but may be a passenger mutation in MLH1-downregulated tumors.